Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$7.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Riad Sherif
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Beta
- 0.23
- Country
- CH
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 6.99
Financials
Revenue
$7.0K-97.2%Net Income
$-18.24MEBITDA
$-17.64MFree Cash Flow
$-18.21MEPS (diluted)
$-0.30Shares Outstanding (diluted)
61.82M+88.8%Operating Expenses
$23.64MCash & Debt
$210.29MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-94.51M | $-1.81 |
| 2024 | $686.0K | $-85.78M | $-2.12 |
| 2023 | $0.00 | $-88.80M | $-2.97 |
| 2022 | $0.00 | $-38.70M | $-1.18 |
| 2021 | $0.00 | $-18.55M | $-0.57 |
| 2020 | $0.00 | $-14.87M | $-0.45 |
Valuation
OCShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-33.33%Social Signal Score
Mentions (24)
- Newsglobenewswire.com·9d ago·Neutral
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today announced that it will host an in-person and virtual R&D Day at St. Regis New York on Tuesday, December 8, 2026, at 10:00 EST/16:00 CET. To register for the event, click here.
View source ↗ - Newszacks.com·16d ago·Neutral
Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Oculis Holding AG (OCS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newszacks.com·19d ago·Negative
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates Oculis Holding AG (OCS) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.4 per share a year ago.
View source ↗ - Newszacks.com·20d ago·Neutral
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis' global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron Tansy, M.D.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit Positive Phase 2 ACUITY trial findings support Privosegtor's potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond
View source ↗ - Newsglobenewswire.com·31d ago·Negative
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
View source ↗ - Newsglobenewswire.com·31d ago·Negative
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…tional data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at the 10th Joint ACTRIMS-ECTRIMS Meet…
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum.
View source ↗ - Newsglobenewswire.com·34d ago·Negative
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
View source ↗ - Newsglobenewswire.com·46d ago·Negative
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
… share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry partner focusing on Vision, officially launching today, on Octobe…
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017…
View source ↗ - Newszacks.com·55d ago·Negative
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS) Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsglobenewswire.com·62d ago·Neutral
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026 HANGZHOU, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- UTStarcom Holdings Corp. (“UT” “UTStarcom” or the “Company”) (NASDAQ: UTSI), a global networking solutions provider, made its inaugural appearance at the 27th China International Optoelectronic Exposition (CIOE 2026), held September 9–11 at the Shenzhen World Exhibition & Convention Center. Exhibiting from a dedicated booth, UTStarcom highlighted its ext…
View source ↗ - Newsglobenewswire.com·66d ago·Neutral
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company's Board of Directors.
View source ↗ - Newszacks.com·83d ago·Positive
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON).
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
View source ↗ - Newsglobenewswire.com·104d ago·Negative
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”),
View source ↗
Earnings
Tue, Mar 2(in 3 months)
Consensus estimate $-0.50 per share
Typical surprise -6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$-0.37 vs $-0.47beat
- Thu, Aug 6$-0.20 vs $-0.48beat
- Mon, May 11$-0.63 vs $-0.49miss
- Tue, Mar 3$-0.51 vs $-0.48miss
- Mon, Nov 10$-0.40 vs $-0.50beat
- Thu, Aug 21$-0.59 vs $-0.53miss
Estimates and results for OCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in OCS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
